The FDA has accepted or received a biologics license application (BLA) for an ivonescimab regimen. The application is related to the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, specifically in patients who have been pretreated or are in the second-line or later stage of treatment. The exact details of the regimen, including whether it is used alone or in combination with chemotherapy, are not consistently reported across outlets.